ChromaDex Co. (NASDAQ:CDXC - Get Free Report) shares fell 5.6% during trading on Thursday . The company traded as low as $7.47 and last traded at $7.39. 62,790 shares changed hands during trading, a decline of 93% from the average session volume of 867,001 shares. The stock had previously closed at $7.83.
Analysts Set New Price Targets
CDXC has been the topic of a number of recent research reports. StockNews.com lowered ChromaDex from a "strong-buy" rating to a "buy" rating in a report on Thursday, March 6th. LADENBURG THALM/SH SH raised their price objective on ChromaDex from $6.80 to $8.10 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Finally, HC Wainwright upped their target price on shares of ChromaDex from $8.00 to $11.00 and gave the stock a "buy" rating in a research note on Monday.
Read Our Latest Report on CDXC
ChromaDex Stock Down 3.6 %
The stock has a 50-day moving average of $5.92 and a 200 day moving average of $5.28. The company has a market capitalization of $587.01 million, a PE ratio of 757.86 and a beta of 2.21.
Insider Activity
In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of ChromaDex stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $6.19, for a total value of $230,026.59. Following the sale, the director now owns 244,179 shares of the company's stock, valued at approximately $1,511,468.01. The trade was a 13.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 9.64% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the company. Squarepoint Ops LLC bought a new stake in ChromaDex in the 4th quarter valued at about $555,000. Two Sigma Investments LP bought a new stake in shares of ChromaDex in the fourth quarter valued at approximately $675,000. State of Wyoming purchased a new stake in shares of ChromaDex during the 4th quarter valued at approximately $39,000. Sherbrooke Park Advisers LLC bought a new position in ChromaDex in the 4th quarter worth approximately $94,000. Finally, ProShare Advisors LLC purchased a new position in ChromaDex in the 4th quarter valued at approximately $74,000. Hedge funds and other institutional investors own 15.41% of the company's stock.
About ChromaDex
(
Get Free Report)
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ChromaDex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ChromaDex wasn't on the list.
While ChromaDex currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
